Gemtuzumab ozogamicin

Gemtuzumab ozogamicin
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetCD33
Clinical data
Trade namesMylotarg
AHFS/Drugs.comMonograph
MedlinePlusa618005
License data
Pregnancy
category
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
Molar mass151500 g·mol−1
 NY (what is this?)  (verify)

Gemtuzumab ozogamicin, sold under the brand name Mylotarg, is an antibody-drug conjugate (a drug-linked monoclonal antibody) that is used to treat acute myeloid leukemia (AML).[5][7][8]

The most common side effects include infection, febrile neutropenia, decreased appetite, hyperglycemia, mucositis, hypoxia, hemorrhage, increased transaminase, diarrhea, nausea, and hypotension.[9] However, the addition of gemtuzumab ozogamicin to standard chemotherapy regimens does not increase infection rates. [10]

  1. ^ a b "Mylotarg Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 17 April 2020. Retrieved 17 August 2020.
  2. ^ AusPAR: Gemtuzumab ozogamicin. Therapeutic Goods Administration (TGA) (Report). October 2020.
  3. ^ "Summary Basis of Decision (SBD) for Mylotarg". Health Canada. 23 October 2014. Retrieved 29 May 2022.
  4. ^ "Mylotarg 5mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 29 October 2019. Retrieved 17 August 2020.
  5. ^ a b Cite error: The named reference Mylotarg FDA label was invoked but never defined (see the help page).
  6. ^ Cite error: The named reference Mylotarg EPAR was invoked but never defined (see the help page).
  7. ^ Cite error: The named reference FDA PR was invoked but never defined (see the help page).
  8. ^ "FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML". U.S. Food and Drug Administration (FDA) (Press release). 1 September 2017. Archived from the original on 12 June 2019. Retrieved 6 September 2017.
  9. ^ Cite error: The named reference FDA gemtuzumab ozogamicin indication change was invoked but never defined (see the help page).
  10. ^ Kyriakidis I, Mantadakis E, Stiakaki E, Groll AH, Tragiannidis A (October 2022). "Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas". Cancers. 14 (20): 5022. doi:10.3390/cancers14205022. PMC 9599435. PMID 36291806.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.